Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

An AI system developed to predict a patient's response to immunotherapy could help "democratize" access to the pricey drugs ...

Financial support options for Paxlovid are changing, but remain in place this winter for Medicare recipients and for others ...

Companies seeking to benefit from campaign promises to cut regulations and taxes are ditching diversity and climate ...

Charleston, W.Va. (WTAP) - West Virginia Attorney General Patrick Morrisey has sent letters to all of the state’s counties ...

A federal appeals court revived a lawsuit on Friday challenging Pfizer Inc.‘s fellowship program aimed at building a diverse ...

Nuvalent's NVL-655 and Zidesamtinib show strong potential as first-line therapies for NSCLC. Click here to find out why I ...

A U.S. appeals court on Friday revived a lawsuit by a conservative group opposed to diversity initiatives in medicine that ...

H.C. Wainwright analyst Andres Maldonado keeps a Buy rating on CG Oncology (CGON) with a $75 price target after Pfizer (PFE) announced positive ...

FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...